Seroprevalence of human T-lymphotropic virus type I or II in sexually transmitted disease clinic patients in the USA

Rima F. Khabbaz, John M. Douglas, Franklyn N. Judson, Richard A. Spiegel, Michael E. St Louis, William Whittington, Trudie M. Hartley, Michael Dale Lairmore, Jonathan E. Kaplan

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Serum specimens from patients attending sexually transmitted disease (STD) clinics in Denver and several southeastern US cities were tested for antibody to human T-lymphotropic virus type I or II (HTLV-I/II). In Denver, 8 (2.1%) of 384 patients with a history of intravenous (IV) drug use, versus none of 201 non-IV-drug users, were HTLV-I/II seropositive. Only 2 (0.18%) of 1095 STD clinic patients from the southeastern USA had antibodies to HTLV-I/II. These data document a low prevalence of HTLV-I/II in STD clinic patients from the southeastern USA and confirm that IV drug use is an important risk factor for HTLV-I/II in the USA.

Original languageEnglish (US)
Pages (from-to)241-244
Number of pages4
JournalJournal of Infectious Diseases
Volume162
Issue number1
StatePublished - Jul 1990
Externally publishedYes

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Fingerprint Dive into the research topics of 'Seroprevalence of human T-lymphotropic virus type I or II in sexually transmitted disease clinic patients in the USA'. Together they form a unique fingerprint.

  • Cite this

    Khabbaz, R. F., Douglas, J. M., Judson, F. N., Spiegel, R. A., St Louis, M. E., Whittington, W., Hartley, T. M., Lairmore, M. D., & Kaplan, J. E. (1990). Seroprevalence of human T-lymphotropic virus type I or II in sexually transmitted disease clinic patients in the USA. Journal of Infectious Diseases, 162(1), 241-244.